$RXST

RxSight, Inc.

CIK:0001111485|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenues	$ 33,741	$ 33,637	$ 64,634	$ 71,531
Costs and expenses:
Cost of sales	7,855	8,447	15,250	18,013
Selling, general and administrative	30,419	28,976	62,274	57,611
Research and development	9,237	10,217	18,709	20,584
Total costs and expenses	47,511	47,640	96,233	96,208
Loss from operations	(13,770)	(14,003)	(31,599)	(24,677)
Other income (expense), net:
Interest expense	(3)	(5)	(6)	(11)
Interest and other income	1,764	2,254	3,718	4,762
Loss before income taxes	(12,009)	(11,754)	(27,887)	(19,926)
Income tax expense	88	32	94	50
Net loss	(12,097)	(11,786)	(27,981)	(19,976)
Other comprehensive loss
Unrealized loss on short-term investments	(5)	(146)	(125)	(303)
Foreign currency translation gain (loss)	13	14	13	20
Total other comprehensive gain (loss)	8	(132)	(112)	(283)
Comprehensive loss	$ (12,089)	$ (11,918)	$ (28,093)	$ (20,259)
Net loss per share:
Basic net loss per share	$ (0.29)	$ (0.29)	$ (0.68)	$ (0.49)
Diluted net loss per share	$ (0.29)	$ (0.29)	$ (0.68)	$ (0.49)
Weighted-average shares used in computing net loss per share:
Weighted-average shares used in computing net loss per share, basic	41,490,889	40,743,786	41,399,010	40,627,363
Weighted-average shares used in computing net loss per share, diluted	41,490,889	40,743,786	41,399,010	40,627,363
Product sales
Revenue:
Total revenues	$ 27,241	$ 33,637	$ 58,134	$ 71,531
License and collaboration revenue
Revenue:
Total revenues	$ 6,500	$ 0	$ 6,500	$ 0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating Activities:
Net loss	$ (27,981)	$ (19,976)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,833	1,561
Provision for bad debts	206	32
Amortization of discount on short-term investments	(3,606)	(4,541)
Stock-based compensation	15,410	15,687
Provision for excess and obsolete inventory	1,176	1,250
Change in operating assets and liabilities:
Accounts receivable	4,664	1,960
Inventories	(6,733)	(4,302)
Receivable from collaboration partner	(10,000)	0
Prepaid and other assets	1,673	1,742
Accounts payable	946	(1,491)
Deferred revenue - collaboration	3,500	0
Accrued expenses and other liabilities	(1,517)	(5,130)
Net cash used in operating activities	(20,429)	(13,208)
Investing Activities:
Purchases of property and equipment	(2,715)	(2,112)
Maturities of short-term investments	210,000	110,000
Purchases of short-term investments	(193,785)	(72,381)
Net cash provided by investing activities	13,500	35,507
Financing Activities:
Proceeds from issuance of common stock	813	2,764
Payments for employee taxes related to stock compensation	(473)	(1,418)
Principal payments on finance lease liabilities	(14)	(16)
Net cash provided by financing activities	326	1,330
Effect of foreign exchange rate on cash, cash equivalents and restricted cash	6	20
Net (decrease) increase in cash, cash equivalents and restricted cash	(6,597)	23,649
Cash, cash equivalents and restricted cash - beginning of period	20,699	17,456
Cash, cash equivalents and restricted cash - end of period	14,102	41,105
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	1,680	1,383
Cash paid for income taxes	144	70
Right-of-use assets obtained in exchange for lease obligations:
Operating lease	211	0
Lease obligations recorded for right-of-use assets:
Operating lease	211	0
Acquisition of property and equipment included in accounts payable and accrued expenses and accrued liabilities	$ 319	$ 250

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 13,352	$ 19,949
Short-term investments	195,447	208,179
Accounts receivable, net	18,519	23,383
Inventories	37,117	31,559
Prepaid and other current assets	2,961	4,389
Receivable from collaboration partner	60,000	0
Total current assets	327,396	287,459
Property and equipment, net	14,039	13,056
Operating leases right-of-use assets	9,491	9,959
Restricted cash	750	750
Other assets	1,024	590
Total assets	352,700	311,814
Current liabilities:
Accounts payable	6,345	5,296
Accrued expenses and other current liabilities	15,553	16,533
Lease liabilities	1,664	1,162
Deferred revenue, current	6,882	3,262
Refund liability	50,000	0
Total current liabilities	80,444	26,253
Long-term lease liabilities	8,916	9,878
Total liabilities	89,360	36,131
Commitments and contingencies (Note 8)
Stockholders' deficit:
Common stock, $0.001 par value, 900,000,000 shares authorized, 41,585,381 shares issued and outstanding as of June 30, 2026 and 41,242,005 shares issued and outstanding as of December 31, 2025	41	41
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	952,378	936,628
Accumulated other comprehensive (loss) income	(59)	53
Accumulated deficit	(689,020)	(661,039)
Total stockholders' equity	263,340	275,683
Total liabilities and stockholders' equity	$ 352,700	$ 311,814